Abstract:Osteoarthritis (OA) is the most common cause of disability worldwide among the elderly. Alarmingly, the incidence of OA in individuals less than 40 years of age is rising, likely due to the increase in obesity and post-traumatic osteoarthritis (PTOA). In recent years, due to a better understanding of the underlying pathophysiology of OA, several potential therapeutic approaches targeting specific molecular pathways have been identified. In particular, the role of inflammation and the immune system has been increasingly recognized as important in a variety of musculoskeletal diseases, including OA. Similarly, higher levels of host cellular senescence, characterized by cessation of cell division and the secretion of a senescence-associated secretory phenotype (SASP) within the local tissue microenvironments, have also been linked to OA and its progression. New advances in the field, including stem cell therapies and senolytics, are emerging with the goal of slowing disease progression. Mesenchymal stem/stromal cells (MSCs) are a subset of multipotent adult stem cells that have demonstrated the potential to modulate unchecked inflammation, reverse fibrosis, attenuate pain, and potentially treat patients with OA. Numerous studies have demonstrated the potential of MSC extracellular vesicles (EVs) as cell-free treatments that comply with FDA regulations. EVs, including exosomes and microvesicles, are released by numerous cell types and are increasingly recognized as playing a critical role in cell–cell communication in age-related diseases, including OA. Treatment strategies for OA are being developed that target senescent cells and the paracrine and autocrine secretions of SASP. This article highlights the encouraging potential for MSC or MSC-derived products alone or in combination with senolytics to control patient symptoms and potentially mitigate the progression of OA. We will also explore the application of genomic principles to the study of OA and the potential for the discovery of OA phenotypes that can motivate more precise patient-driven treatments.

Combating Osteoarthritis through Stem Cell Therapies by Rejuvenating Cartilage: A Review

Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis

The Current State of Osteoarthritis Treatment Options Using Stem Cells for Regenerative Therapy: A Review

Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions

Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis

Advantages and challenges of stem cell therapy for osteoarthritis (Review)

Advancements in Inflammation Control and Cartilage Regeneration

Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives

Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee

Adipose-derived stem cells in articular cartilage regeneration: current concepts and optimization strategies.

Cell Therapy Approaches for Articular Cartilage Regeneration

Current Non-Surgical Curative Regenerative Therapies for Knee Osteoarthritis

Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration

Current Research on Pharmacologic and Regenerative Therapies for Osteoarthritis

Articular cartilage regeneration by activated skeletal stem cells

Exploring Orthopedic Stem-Cell Approaches for Osteoarthritis Management: Current Trends and Future Horizons

Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis

Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents

Botanical Drug Extracts Combined With Biomaterial Carriers for Osteoarthritis Cartilage Degeneration Treatment: A Review of 10 Years of Research

Role of Chondrocytes in Cartilage Formation, Progression of Osteoarthritis and Cartilage Regeneration

Advances in cartilage tissue regeneration: a review of stem cell therapies, tissue engineering, biomaterials, and clinical trials